Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020115257 - COLONIC DRUG DELIVERY FORMULATION

Publication Number WO/2020/115257
Publication Date 11.06.2020
International Application No. PCT/EP2019/083912
International Filing Date 05.12.2019
IPC
A61K 9/28 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
28Dragees; Coated pills or tablets
A61K 31/606 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
60Salicylic acid; Derivatives thereof
606having amino groups
CPC
A61K 31/606
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
60Salicylic acid; Derivatives thereof
606having amino groups
A61K 9/2846
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, tablets, ; discs, rods
28Dragees; Coated pills or tablets ; , e.g. with film or compression coating
2806Coating materials
2833Organic macromolecular compounds
284obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
2846Poly(meth)acrylates
A61K 9/2853
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, tablets, ; discs, rods
28Dragees; Coated pills or tablets ; , e.g. with film or compression coating
2806Coating materials
2833Organic macromolecular compounds
2853obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
A61K 9/286
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, tablets, ; discs, rods
28Dragees; Coated pills or tablets ; , e.g. with film or compression coating
2806Coating materials
2833Organic macromolecular compounds
286Polysaccharides, e.g. gums; Cyclodextrin
A61K 9/2866
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, tablets, ; discs, rods
28Dragees; Coated pills or tablets ; , e.g. with film or compression coating
2806Coating materials
2833Organic macromolecular compounds
286Polysaccharides, e.g. gums; Cyclodextrin
2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Applicants
  • TILLOTTS PHARMA AG [CH]/[CH]
Inventors
  • VARUM, Felipe
  • BRAVO GONZÁLEZ, Roberto Carlos
Agents
  • BECK GREENER LLP
Priority Data
18211141.907.12.2018EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) COLONIC DRUG DELIVERY FORMULATION
(FR) FORMULATION POUR L'ADMINISTRATION D'UN MÉDICAMENT POUR LE CÔLON
Abstract
(EN)
In a delayed release drug formulation comprising a core containing a drug and optionally and a delayed release coating for intestinal release, release of the drug in the colon is not hindered by the absence of an alkaline middle layer between the core and the outer layer. The delayed release coating comprising and inner coating and optionally an isolation layer. The outer coating comprises a mixture of an enzymatically degradable polysaccharide which is degradable by colonic enzymes selected from the group consisting of starch, amylose, amylopectin, chitosan, chondroitin sulfate, cyclodextrin, d extra n, pullulan, carrageenan, scleroglucan, chitin, curdulan, and levan; and a film-forming enteric polymer having a pH threshold at about pH 6 or above, wherein the enzymatically degradable polysaccharide and the enteric polymer are present in the outer coating in a ratio of more than 60:40.
(FR)
La présente invention porte sur une formulation de médicament à libération retardée comprenant un cœur contenant un médicament et éventuellement un enrobage à libération retardée pour la libération intestinale, la libération du médicament dans le côlon n'étant pas entravée par l'absence d'une couche alcaline médiane entre le cœur et la couche externe. L'enrobage à libération retardée comprend un revêtement interne et éventuellement une couche d'isolation. Le revêtement externe comprend un mélange d'un polysaccharide dégradable par voie enzymatique qui est dégradable par des enzymes du côlon sélectionnées dans le groupe constitué par l'amidon, l'amylose, l'amylopectine, le chitosane, le sulfate de chondroïtine, la cyclodextrine, le dextrane, le pullulane, le carraghénane, le scléroglucane, la chitine, le curdulane et levane ; et un polymère entérique filmogène ayant un pH seuil à environ 6 ou plus, le polysaccharide dégradable par voie enzymatique et le polymère entérique étant présents dans le revêtement externe en un rapport supérieur à 60:40.
Also published as
Latest bibliographic data on file with the International Bureau